Impel Pharmaceuticals Total Revenue

The latest total revenue for IMPL is $21M as of September 2023. That compares with $8.2M in the prior-year period — up 155.3% year over year. That is below the Healthcare sector average of $11T. Investors often review this figure alongside Impel Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, IMPL's total revenue moved from $8.2M to $21M — a 155.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Impel Pharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, IMPL currently prints $21M for total revenue, while the sector average sits near $11T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Impel Pharmaceuticals's growth, margins, and balance sheet.

A total revenue figure of $21M for IMPL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $11T. Explore the charts below for those layers of context.

After noting IMPL's total revenue ($21M), review year-over-year change from $8.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.